Trials / Sponsors / Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Industry · 3 registered clinical trials — 3 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer | Phase 1 | 2026-04-01 |
| Recruiting | Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies Relapsed or Refractory B-cell Malignancies | Phase 1 | 2025-03-31 |
| Recruiting | Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | 2023-07-06 |